Wells Fargo cuts Stryker stock price target on revenue concerns

Wells Fargo has increased its price target for Pharvaris B.V. (NASDAQ:PHVS) stock to $65 from $55, maintaining an Overweight rating. The current stock price is $37.84, with analysts setting targets ranging from $40.31 to $79.01. Pharvaris shares have shown a 58% return over the past year, indicating growing investor confidence in the company's clinical pipeline.

The firm highlighted strong efficacy data for deucrictibant, which demonstrated an 83% reduction in attack rates compared to placebo across all hereditary angioedema (HAE) subtypes, with an even more impressive 87% reduction in Types 1 and 2. Wells Fargo now believes there is a 90% probability of success in the prophylactic indication for deucrictibant XR when using a discounted cash flow-based price target.

Deucrictibant XR's performance in HAE Types 1 and 2 surpasses that of other oral therapies, including TAKHZYRO, ANDEMBRY, and DAWNZERA, which only tested in Type 1 and 2. The drug reduced attack rates by 83% in all HAE types, with statistical significance in every case. In the company's recent Chapter 3 pivotal Phase 3 study, deucrictibant XR showed an 83% reduction in attack rates compared to placebo, and an 87% reduction for HAE Types 1 or 2.

The trial met its primary endpoint, and 90% of patients achieved at least a 50% reduction in attacks. Pharvaris has received positive top-line data from this pivotal study, with Oppenheimer and Citizens raising their price targets accordingly. H.C. Wainwright and the European Medicines Agency are also supporting the drug's potential, with a Buy rating and Market Outperform rating, respectively.